Profile data is unavailable for this security.
About the company
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
- Revenue in USD (TTM)15.61m
- Net income in USD-119.48m
- Incorporated2020
- Employees136.00
- LocationLiquidia Corp419 Davis Drive, Suite 100MORRISVILLE 27560United StatesUSA
- Phone+1 (919) 328-4400
- Fax+1 (919) 328-4402
- Websitehttps://www.liquidia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals Inc | 26.27m | -339.45m | 596.93m | 452.00 | -- | -- | -- | 22.72 | -5.69 | -5.69 | 0.4398 | -2.74 | 0.0842 | 2.68 | -- | 58,119.47 | -108.79 | -83.26 | -126.95 | -93.77 | 83.54 | -- | -1,292.14 | -135,982.00 | 5.68 | -5.60 | 1.56 | -- | -- | -- | -1.96 | -- | -- | -- |
| Eyepoint Pharmaceuticals Inc | 45.71m | -103.57m | 609.80m | 121.00 | -- | 2.19 | -- | 13.34 | -2.01 | -2.01 | 0.9018 | 4.09 | 0.1983 | 1.05 | 106.19 | 377,793.40 | -44.94 | -40.44 | -59.48 | -47.79 | 91.48 | 83.45 | -226.57 | -186.23 | 5.45 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| CorMedix Inc | 12.26m | -46.15m | 651.67m | 82.00 | -- | 10.59 | -- | 53.14 | -0.8011 | -0.8011 | 0.212 | 1.01 | 0.1451 | -- | -- | 149,539.50 | -54.61 | -54.84 | -64.60 | -62.32 | 83.57 | 6.18 | -376.35 | -18,323.42 | 3.60 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Elite Pharmaceuticals Inc | 66.45m | 19.58m | 708.80m | 64.00 | 34.68 | 12.17 | 33.66 | 10.67 | 0.0191 | 0.0191 | 0.064 | 0.0545 | 0.9892 | 2.91 | 4.98 | 1,038,252.00 | 29.15 | 19.07 | 36.18 | 24.29 | 45.27 | 46.63 | 29.47 | 20.77 | 2.09 | 1.44 | 0.1389 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| Pliant Therapeutics Inc | 0.00 | -201.68m | 774.67m | 158.00 | -- | 2.24 | -- | -- | -3.34 | -3.34 | 0.00 | 5.68 | 0.00 | -- | -- | 0.00 | -40.90 | -33.24 | -43.90 | -35.39 | -- | -- | -- | -360.29 | -- | -- | 0.0802 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Avid Bioservices Inc | 142.36m | -144.17m | 781.54m | 371.00 | -- | 13.29 | -- | 5.49 | -2.27 | -2.27 | 2.24 | 0.9192 | 0.3661 | 3.81 | 4.32 | 383,714.30 | -37.08 | -0.826 | -57.59 | -1.20 | 6.27 | 19.26 | -101.27 | -2.14 | 1.05 | -3.18 | 0.7343 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
| Pacira Biosciences Inc | 694.96m | -90.73m | 786.33m | 711.00 | -- | 1.05 | -- | 1.13 | -2.15 | -2.15 | 13.03 | 16.24 | 0.4548 | 1.71 | 7.03 | 977,436.00 | -5.94 | 3.35 | -6.83 | 3.98 | 74.35 | 72.63 | -13.06 | 8.57 | 1.89 | -- | 0.4393 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Evolus Inc | 248.33m | -55.46m | 799.75m | 322.00 | -- | 135.63 | -- | 3.22 | -0.9141 | -0.9141 | 4.11 | 0.0931 | 1.25 | 4.59 | 6.61 | 909,619.10 | -27.90 | -40.92 | -38.48 | -59.74 | 69.94 | 65.43 | -22.33 | -80.46 | 2.23 | -2.04 | 0.9537 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Liquidia Corp | 15.61m | -119.48m | 850.07m | 136.00 | -- | 7.74 | -- | 54.46 | -1.62 | -1.62 | 0.2111 | 1.31 | 0.0857 | -- | 4.14 | 114,779.40 | -65.55 | -55.02 | -75.02 | -62.69 | 64.65 | 82.18 | -765.37 | -474.59 | 6.33 | -31.14 | 0.5059 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Phibro Animal Health Corp | 1.05bn | 17.41m | 947.38m | 1.94k | 54.49 | 3.66 | 17.64 | 0.9051 | 0.4293 | 0.4293 | 25.82 | 6.38 | 1.08 | 2.60 | 6.75 | 539,568.10 | 1.80 | 3.93 | 2.20 | 4.90 | 31.47 | 31.18 | 1.66 | 3.77 | 1.69 | 2.20 | 0.6472 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| Collegium Pharmaceutical Inc | 599.25m | 88.59m | 967.51m | 197.00 | 15.00 | 4.13 | 4.09 | 1.61 | 2.00 | 2.00 | 13.05 | 7.27 | 0.4261 | 6.25 | 2.92 | 3,041,853.00 | 6.30 | 2.79 | 9.38 | 4.80 | 62.36 | 50.88 | 14.78 | 5.16 | 0.8832 | 3.94 | 0.7873 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 138.16m | -72.58m | 1.03bn | 154.00 | -- | 13.87 | -- | 7.49 | -0.7894 | -0.7894 | 1.48 | 0.775 | 0.7647 | 1.04 | 6.38 | 897,142.90 | -40.17 | -40.21 | -54.87 | -47.99 | 91.92 | -- | -52.53 | -374.75 | 2.60 | -6.11 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 555.46m | -8.77m | 1.16bn | 642.00 | -- | 2.86 | 22.45 | 2.09 | -0.4489 | -0.4489 | 28.67 | 20.44 | 0.5102 | 1.75 | 2.96 | 865,196.30 | -0.6514 | -2.83 | -0.7654 | -3.35 | 59.79 | 60.18 | -1.28 | -6.15 | 1.97 | 0.7018 | 0.5921 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Tilray Brands Inc | 812.04m | -212.62m | 1.17bn | 2.65k | -- | 0.3247 | -- | 1.43 | -0.2746 | -0.2746 | 1.03 | 3.97 | 0.1875 | 2.31 | 8.73 | 306,429.10 | -4.64 | -- | -5.15 | -- | 29.42 | -- | -24.78 | -- | 1.57 | -1.16 | 0.0953 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Liquidia Corp's reporting currency: US Dollar USD
37.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Caligan Partners LPas of 30 Sep 2024 | 8.12m | 9.75% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.77m | 4.52% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.29m | 3.96% |
| Farallon Capital Management LLCas of 30 Sep 2024 | 3.29m | 3.95% |
| Findell Capital Management LLCas of 30 Sep 2024 | 3.19m | 3.84% |
| Kynam Capital Management LPas of 30 Sep 2024 | 2.27m | 2.72% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.18m | 2.61% |
| Whitefort Capital Management, LPas of 30 Sep 2024 | 1.70m | 2.04% |
| Opaleye Management, Inc.as of 30 Sep 2024 | 1.70m | 2.04% |
| Vestal Point Capital LPas of 30 Sep 2024 | 1.50m | 1.80% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
